287 related articles for article (PubMed ID: 21224838)
1. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
Johnson D; Crawley JA; Hwang C; Brown K
Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
[TBL] [Abstract][Full Text] [Related]
5. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Johnson DA; Katz PO
Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
[TBL] [Abstract][Full Text] [Related]
6. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
[TBL] [Abstract][Full Text] [Related]
7. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
8. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Kindt S; Imschoot J; Tack J
Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
[TBL] [Abstract][Full Text] [Related]
11. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
12. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
Lee JH; Kim MJ; Lee JS; Choe YH
Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
[TBL] [Abstract][Full Text] [Related]
13. Endoluminal gastroplication for the treatment of gastroesophageal reflux disease: a 2-year prospective pilot study from Taiwan.
Liao CC; Lee CL; Lin BR; Bai CH; Hsieh YH; Wu CH; Gostout CJ
J Gastroenterol Hepatol; 2008 Mar; 23(3):398-405. PubMed ID: 18318824
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
15. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
[No Abstract] [Full Text] [Related]
16. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
[TBL] [Abstract][Full Text] [Related]
17. Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study.
Kahrilas PJ; Howden CW; Wernersson B; Denison H; Nuevo J; Gisbert JP
Aliment Pharmacol Ther; 2013 May; 37(10):1005-10. PubMed ID: 23557078
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.
Rush DR; Stelmach WJ; Young TL; Kirchdoerfer LJ; Scott-Lennox J; Holverson HE; Sabesin SM; Nicholas TA
J Fam Pract; 1995 Aug; 41(2):126-36. PubMed ID: 7636452
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
20. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
